Older Melanoma Patients Respond Better to Anti-PD-1 Immunotherapies, Study Shows
June 26, 2018
Written by
Photo credit: Immuno-Oncology News
Older melanoma patients respond better to the anti-PD-1 immunotherapy Keytruda (pembrolizumab), according to new data from a multinational study. Researchers are attributing these differences to a reduced immunosuppressive tumor environment in older patients.
The study with these findings, “Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations,” was published in Clinical Cancer Research. Read more.
Published June 20, 2018 by Immuno-Oncology News
Share this story
‹ More Featured Studies